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Abstract According to the 'protein only' hypothesis, modifica-
tion of the 3-dimensional fold of the constituent cellular protein, 
P r P c , into the disease-associated isoform, PrP S c , is the cause of 
neurodegenerative diseases in animals and humans. Here we 
describe the high-level synthesis in Escherichia coli, and 
purification in the monomeric form, of a histidine-tagged full-
length mature PrP (25-249) of bovine brain, termed His-PrP. 
Based on biochemical and spectroscopic data, His-PrP displays 
characteristics expected for the P r P c isoform. The reported 
expression system should allow the production of quantities of 
bovine P r P c sufficient to permit 3-dimensional structure 
determinations. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Intense interest is nowadays focussed on a group of trans-
missible neurodegenerative diseases among which are spongi-
form encephalopathy of ox, scrapie of sheep, and Creutzfeldt-
Jakob disease of humans. These diseases can be transmitted 
by an infectious agent, called prion, which appears to be of a 
proteinaceous nature [1]. The tenet of the 'protein only' hy-
pothesis formulated by Prusiner [2] to explain prion diseases 
holds that a post-translational structural change converts the 
cellular constituent protein, P r P c , to the pathogenic isoform, 
PrPS c [3-5], which is chemically identical to the native protein 
[6] but with an altered sensitivity to proteases [7,8], different 
solubility and tinctorial properties [9] as well as a distinct 
cellular distribution [10]. Elucidating the structure of prion 
isoforms is fundamental to understanding the molecular 
mechanism of the hypothesised structural transition. In spite 
of much effort devoted to the 3-dimensional analysis of PrP, 
p rpSc i n s o i u bi l i ty or the low yield of purified P r P
c [3,11], have 
hindered progress. Results have been equally unsatisfactory 
when the heterologous expression of several constructs of 
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P r P c was probed in a variety of systems [11-15]. Recently, 
by exploiting fusion proteins expressed in the periplasm of 
Escherichia coli, spectroscopic or N M R studies have been 
carried out on hamster [16] and mouse [17,18] PrP fragments, 
which reside within the protein core of infectivity [19]. 
To approach this problem, we have now expressed intra-
cellularly in bacteria the full-length mature part of bovine PrP 
(25-249) fused at its N-terminus to a hexahistidine extension 
(His-PrP). The bovine protein was chosen in view of the im-
portant health concerns raised by bovine spongiform enceph-
alopathy and because its structure has been less extensively 
studied among prions. A three-step procedure, consisting of 
extraction from inclusion bodies with guanidinium chloride, 
and purification by immobilised Ni(II) chromatography and 
reverse-phase H P L C was used to recover monomeric His-PrP 
in high yields. Biochemical and spectroscopic evidence identi-
fied (the prion sequence of) His-PrP with the naturally occur-
ring PrP isoform. 
2. Materials and methods 
2.1. Materials 
Restriction enzymes and T4 DNA ligase were purchased from Gib-
co-BRL and proteolytic enzymes from Boehringer. Oligonucleotides 
were synthesised with an Applied Biosystems 380B DNA synthesiser. 
Plasmid pRSETA was purchased from Invitrogen, while host cell lines 
E. coli BL21 (DE3) LysE and HB101 were obtained from Novagen. 
Plasmids were constructed in E. coli HB101 and verified by double-
stranded dideoxynucleotide sequencing using a Sequenase kit (United 
States Biochemical). Cloning procedures were essentially as in [20]. 
2.2. Construction of plasmid pRSETA-PrP 
Oligonucleotides derived from the 5' and 3' coding regions of the 
bovine PrP gene were used to amplify the mature sequence by PCR, 
using cDNA templates generated from bovine brain mRNA. Oligo-
nucleotide primers (5'-cgctcgactcaAAGAAGCGACCAAAACCTG-
GA-3' (forward sequence); 5'-cccatatgTCGTTGGTAATAAGCCT-
GGGATTCT-3' (reverse sequence)) were placed between bp 72 and 
93, and bp 693 and 717, respectively, of the bovine PrP sequence [21]. 
After a 5-min incubation at 94°C, samples were subjected to 32 cycles 
of PCR as in [20]. PCR products were purified [20], digested with Sail 
and Ndel, and subcloned between the same restriction sites in pGEM5 
to give the pGEM-PrP plasmid. pGEM5-PrP was finally digested with 
Sad and EcoKV and subcloned between Sad and Pvull in pRSETA 
to produce plasmid pRSETA-PrP (Fig. 1A). 
2.3. Synthesis and purification of His-PrP 
Freshly prepared cultures of E. coli BL21 (DE3) LysE cells trans-
formed with pRSETA-PrP were grown at 37°C in Luria's broth con-
taining 0.1% ampicillin, until reaching an absorbance (at 590 nm) of 
0.5 [20]. Protein synthesis was induced by addition of 0.4 mM iso-
propyl-p-D-thiogalactopyranoside, and 3 h later bacteria were har-
vested. Recombinant protein was extracted from inclusion bodies by 
resuspending bacterial cells (0.1 g of wet pellet weight per ml) in 6 M 
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guanidine-HCl, 0.1 M NaH 2P0 4 , 10 mM Tris-HCl, pH 8.0, and son-
ication [22]. The lysate was cleared by centrifugation at 28000Xg for 
20 min, and then filtered through a 0.45 urn (Millipore) membrane. 
The filtrate was applied to a column (1x4 cm) of Ni(II)-nitriloacetate 
agarose (Ni(II)-NTA; Diagen) [23]. After exhaustive washing with 8 M 
urea, 0.1 M NaH2P04 and 10 mM Tris-HCl (pH 8.0), His-PrP was 
eluted by shifting the pH to 4.5. Protein refolding was accomplished 
by a 3-day dialysis against 50 mM sodium acetate, pH 4.0. Further 
purification was achieved by reverse-phase HPLC using a 0.46 X 15 cm 
C4 column (Vydac) equilibrated with 0.05% (v/v) aqueous TFA. The 
sample was eluted using a 5-25% acetonitrile gradient (in 0.05% TFA) 
in 10 min and 25-50% acetonitrile in 40 min, at a flow rate of 0.6 ml/ 
min. His-PrP eluted at 37% acetonitrile and was then lyophilised. 
Stock solutions of His-PrP (1 mg/ml) in 10 mM sodium acetate, pH 
4.0, were stored at -80°C. 
2.4. SDS-PAGE and Western blotting 
SDS-PAGE was performed according to [24]. Proteins were stained 
with Coomassie Blue. For Western blotting, after SDS-PAGE samples 
were electro-transferred overnight (40 mA) to Immobilon (PVDF) 
membranes (Millipore). The membranes were saturated for 1 h with 
3% gelatin in Tris-Tween buffer solution, then incubated 2 h with 
1:500 rabbit polyclonal antibodies against PrP (see below). Bound 
antibodies were visualised by use of the Auroprobe kit (Janssen). 
Antibodies were raised against the following bovine PrP amino acid 
sequences: 102-119 (GQGGTHGQWNKPSKPKTN) and 153-168 
(GSDYEDRYYRENMHRY). Peptides were synthesized using a 
Millipore Milligen 9050 synthesiser (Milford, MA), purified by re-
verse-phase HPLC, and verified by amino acid analysis. Antisera 
were produced by immunizing female New Zealand white rabbits. 
Antibody titer was evaluated by standard ELISA techniques using 
peptide-coated micro wells. The IgG fraction was precipitated with 
caprylic acid and purified by affinity chromatography [25]. 
2.5. N-terminal sequencing 
Proteins were separated by SDS-PAGE and electrotransferred to 
PVDF membranes (ProBlott, Applied Biosystems) and visualised 
with Coomassie Blue. Sequencing was then performed by automated 
Edman degradation using an Applied Biosystems 477A sequencer, 
according to the manufacturer's protocols. 
2.6. Protein concentration 
Concentrations of His-PrP solutions were determined by UV ab-
sorbance spectroscopy, using a double-beam Perkin-Elmer Lambda 2 
spectrophotometer and 1-cm path length quartz cuvettes. An extinc-
tion coefficient for His-PrP of 2.68 mg_ 1 cm2 at 280 nm was calcu-
lated according to Gill and von Hippel [26]. 
2.7. Protein digestion 
Proteinase K (0.6 ug) was added to 10 ug of His-PrP in 25 ul final 
volume of 50 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 0.1% octyl-P-D-
glycopyranoside. Digestion was carried out as in [8]. Endoproteinase 
LysC (1 (ig) was added to 100 ug of His-PrP in 200 ul final volume of 
50 mM sodium acetate, pH 6.0. Digestion was carried out at room 
temperature and was stopped by adding 0.1% TFA and heating in a 
boiling water bath for 5 min. In either case, digestion products were 
examined by SDS-PAGE; endo LysC products were also controlled 
by mass spectrometry. 
2.8. CD spectroscopy 
His-PrP samples were dialysed 24 h against 10 mM sodium phos-
phate buffer (pH 3.5 or pH 6.5) and adjusted to 300-600 ug protein/ 
ml. A JASCO J-710 spectropolarimeter, fitted with a thermostatted 
cell holder and interfaced with a Neslab RTE-110 water bath (New-
ington, NY), was calibrated with (+)-10-camphor sulfonic acid [27]. 
CD spectra were recorded at 25°C using 0.2-cm (190-250 nm region) 
or 0.5-cm (250-320 nm region) path length quartz cuvettes. Values are 
expressed as mean residue ellipticity ([©]MRW) [28]. Four consecutive 
accumulations were averaged after subtraction of the corresponding 
buffer baseline. 
2.9. Mass spectrometry 
Mass spectra were accumulated using a Voyager Elite MALDI 
TOF mass spectrometer (Perseptive Biosystems, Framingham, MA). 
The starting material for all mass spectrometric determinations was 
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His-PrP purified by reverse-phase HPLC. Protein solutions were ad-
justed to pH 2.0 with 10% TFA. Test samples (0.5 |xl) were mixed with 
an equal volume of matrix solution (5 mg/ml oe-cyano-4-hydroxy-cin-
namic acid in 50% acetonitrile, 0.1% TFA in water) and spotted 
directly onto the MALDI sample target. Samples were analysed in 
pulsed extraction linear mode using an accelerating voltage of 25 kV, 
a pulse delay time of 100 ns, a grid voltage of 91% and guide wire 
voltage of 0.1%. Spectra were accumulated for 64 lasershots. Cyto-
chrome c (horse heart, average mass 12361) was the internal cali-
brant. Samples were also analysed in pulsed extraction reflector mode. 
3. Results 
3.1. Expression and purification of His-PrP 
The expression plasmid pRSETA-PrP (Fig. 1A) codes for a 
fusion protein of 265 amino acids, in which the bovine P rP 
sequence 25-249 was linked into a 40-amino-acid N-terminal 
extension containing a hexahistidine stretch (Fig. IB), thereby 
facilitating purification by immobilized Ni(II) chromatogra-
phy [23]. Nucleotide sequencing of pRSETA-PrP verified its 
identity with the bovine P rP c D N A sequence of Goldmann et 
al. [21]. Fig. 2A (left gel) shows an SDS-PAGE of E. coli 
BL21 (DE3) LysE cells transformed with either pRSETA-
PrP (lane 1), or with two other plasmids lacking the bovine 
PrP sequence (lanes 2 and 3). Only the former cells synthe-
sised a protein of M r » 30 K, a value close to the molecular 
mass of the putative bovine His-PrP (calculated average MT: 
29089.8). This 30 k D a band accounted for approximately 5% 
of total bacterial protein. Test of the same samples of the left 
gel for crossreactivity with antibodies against PrP peptides 
153-168 (Fig. 2A, middle gel) and 102-119 (Fig. 2A, right 
gel) further supports the identity of the 30 k D a band as 
His-PrP. 
His-PrP extraction from inclusion bodies was carried out 
with 6 M guanidine-HCl. The cell extract was then loaded 
onto a Ni(II)-agarose affinity column. His-PrP eluted as a 
major fraction when the p H was lowered from 8.0 to 4.5, 
and was refolded upon urea removal by dialysis at p H 4.0. 
Elution and dialysis buffers were kept acidic, as neutral or 
alkaline p H caused substantial precipitation of His-PrP. 
Reducing SDS-PAGE of the refolded protein showed a 
major, single band of around 30 k D a (Fig. 2B, right gel, 
lane 1). Conversely, under non-reducing conditions His-PrP 
Table 1 
Molecular masses of His-PrP and of the 60 min endo LysC digests 
Residues" 
1-265 
1- 31 
1-133 
1-137 
32-133 
42-133 
134-265 
138-212 
222-265 
Observed massb 
29094 
33 547.2 
13 858.7 
14325.1 
10 329.7 
9155.5 
15252.1 
8413.3 
5 379.9 
Calculated massc 
29089.8 
3 546.8 
13 858.8 
14333.4 
10331.0 
9156.8 
15250.1 
8414.3 
5381.0 
aHis-PrP (1-265), present in the fraction eluting from reverse-phase 
HPLC at 37% acetonitrile, was subjected to proteolysis by endo LysC 
as described in Section 2. 
bMasses were measured by a Voyager Elite MALDI TOF mass spec-
trometer on samples treated as described in Section 2 (desalted), pep-
tides with mass up to 1500 were considered as monoisotopic, while for 
peptides above 1500 mass the average isotopic mass was taken. All 
peptides were considered as single protonated. Quoted values are the 
means of at least five different spectra. 
cGiven masses of the (desalted) peptides were calculated as above. 
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Xhol/Sall 
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EcoRI 
B 
1 MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSELDSKKRPKPGGGW 34 
51 NTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGW 84 
101 GQPHGGGWGQPHGGGGWGQGGTHGQVmKPSKPKTNMKHVAGAAAAGAVVG 134 
151 GLGGYMLGSAMSRPLIHFGSDYEDRYYRENMHRYPNQVYYRPVDQYSNQN 184 
201 NFV^DCVNITVKEHTVTTTTKGENFTETDIKMMERVVEQMCITQYQRESQ 234 
251 AYYQRHMGELEEFEA 249 
Fig. 1. A: Structure of the expression vector coding fusion protein His-PrP. Note insertion of the bovine prion sequence between restriction 
sites Xho\ and EcoRI. T7 promoter indicates the direction of transcription. B: Deduced amino acid sequence translated by pRSETA-PrP. 
Single underlining indicates the N-terminal extension which was fused into the bovine 25-249 PrP sequence. Residues identified by Edman deg-
radation are double underlined. The numbering on the left indicates the amino acid sequence of His-PrP, whereas that on the right refers to 
the deduced bovine prion sequence only. 
yielded bands representing multiples of 30 kDa (Fig. 2B, left 
gel, lane 1), most probably the result of interchain S-S bond 
formation. As our aim was to isolate monomeric His-PrP, the 
refolded protein mixture was further purified by reverse-phase 
HPLC, producing three peaks (Fig. 2C). Only the first peak 
(eluting at 37% acetonitrile) was utilized for all subsequent 
studies, given its purity (Fig. 2B, lanes 2) and average molec-
ular mass of 29 094 determined by mass spectrometry (Table 
1). Although a cleavage site specific for enterokinase 
(DDDDK) was placed within the N-terminal extension of 
His-PrP (Fig. IB) to permit later removal of this tag, the 
expected proteolysis failed to occur (see also [29]). 
3.2. Protease sensitivity of His-PrP 
A major difference between PrPc and PrPSc is the sensitivity 
of PrPc to proteinase K [7,8]. Incubation of His-PrP with 
proteinase K produced complete protein digestion, supporting 
the notion that His-PrP contains the normal cellular isoform, 
PrPc (data not shown). 
His-PrP was next incubated with endoproteinase LysC to 
evaluate accessibility of the 11 lysine residues in His-PrP some 
of which, adjacent to prolines (Lys45; Lys128; Lys131), were 
expected to have a limited reactivity. A 15-min digestion of 
His-PrP with endo LysC produced a major band (MT: = 1 5 
kDa), along with a fainter band (MT: = 9 kDa) on SDS-
PAGE (Fig. 3, lane 2). A 60-min digestion, however, mark-
edly increased the ~ 9 kDa band, while causing the ~ 15 kDa 
band to decrease in intensity with the concomitant appearance 
of a new band just below 15 kDa (Fig. 3, lane 3). N-terminal 
sequencing of this last polypeptide (HVAGAAAAG) and of 
the ~ 9 kDa one (KRPKPGGGW), together with mass spec-
trometric analysis of the 60-min digestion products (Table 1), 
identified these two species with His-PrP peptides 138-265 and 
42-133, respectively. These data, and the other peptides iden-
tified by mass spectrometry (Table 1), suggest that Lys133 is 
the first lysine attacked by endo LysC (after 15 min). Of the 
two peptides so formed, 1-133 and 134-265, only the latter is 
clearly visible (Fig. 3, lane 2), because peptide 1-133 is imme-
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Fig. 2. Verification of synthesis of His-PrP by E. coli by SDS-
PAGE and Western blotting (A) and of His-PrP purification by 
SDS-PAGE (B) and reverse-phase HPLC (C). A: Lanes were loaded 
with 10 (Xg protein from E. coli BL21 (DE3) LysE cells transformed 
with pRSETA-PrP (lanes 1) or with plasmids pRSETA (lanes 2) 
and pT7.7hCNTF [36] (lanes 3), which lack the bovine PrP se-
quence. Proteins were separated on a 12% SDS-PAGE gel (left gel) 
and then tested for crossreactivity with antibodies against the bovine 
PrP peptides 153-168 (middle gel) and 102-119 (right gel). B: His-
PrP (5 |xg/lane) was separated on a 15% SDS-PAGE gel under non-
reducing and reducing (plus 5% P-mercaptoethanol) conditions. 
Lanes 1: His-PrP purified by Ni(II)-aflinity chromatography and re-
folded. Lanes 2 and 3: fractions eluted by reverse-phase HPLC at 
37% and 41% acetonitrile, respectively. C: Reverse-phase HPLC 
chromatogram of refolded His-PrP. Only the peak at 37% acetoni-
trile was used further. 
diately processed at Lys41 thus producing the ~ 9 kDa band 
(peptide 42-133) (Fig. 3, lane 2). While peptide 1-133 is con-
tinuously digested at Lys41, Lys137 of peptide 134-265 is at-
tacked only at later times along with other lysines (Lys31, 
Lys212, Lys221), as shown by mass determination of the 60-
min digests (Table 1) and the electrophoretic patterns of the 
60- and 120-min products (Fig. 3, lanes 3, 4). Prolonged (24 h) 
digestion resulted in the formation of several other fragments, 
some of which were already present after 120 min (Fig. 3, 
lane 4). 
3.3. Spectroscopic studies of His-PrP 
Far-UV CD spectra of His-PrP (Fig. 4A), recorded at pH 
3.5 and pH 6.5, showed a maximum at 190 nm and two 
minima centered at 208 nm and 220 nm. His-PrP may thus 
contain a substantial amount of a-helical structure at either 
pH [28], although decrease of the 220 nm signal at pH 3.5 
suggests a diminishing oc-helix contribution with decreasing 
pH (from approximately —8000 deg-cm2-dmol_1 at pH 6.5 
to —7000 deg-cm2-dmol_1 at pH 3.5). The overall features 
at near-UV (at pH 3.5) (Fig. 4B) point to the presence of a 
tertiary structure of the protein. Indeed, in the 275-285 nm 
region the spectrum is dominated by tyrosine absorption, and 
in the 260-270 nm region by phenylalanine absorption, a pro-
file diagnostic for fine structures. The distinct positive peak at 
296 nm suggests that some tryptophanyl residues are located 
in a rigid and asymmetric environment [28]. 
4. Discussion 
The 'protein only' hypothesis of prion diseases critically 
depends on an understanding of the molecular mechanism 
leading to the generation of PrPSc from PrPc which, in 
turn, requires a knowledge of the 3-dimensional structure of 
both protein isoforms. Structural studies of PrPc, however, 
have been hampered by low levels of expression in mamma-
lian cells [11-14,30] and by difficulties encountered in adopt-
ing heterologous expression systems [15]. For example, the 
recent periplasmic expression in E. coli of prion constructs 
linked to secretion vectors produced PrPs lacking mature 
N-terminal sequences of various lengths, either because of 
proteolysis in the periplasmic space [17,18] or because of 
poor expression of the full-length mature protein, alone or 
as a fusion protein [16]. At variance with previous heterolo-
gous expression attempts, the present study reports on the 
intracellular synthesis in bacteria of an histidine-tagged ma-
ture bovine prion protein, fully resistant to cellular degrada-
tion. 
Recovery of the recombinant protein was maximized by use 
of guanidinium chloride for inclusion body extraction, a low 
pH to guarantee protein solubility, and a hexahistidine tag to 
permit purification by immobilized Ni(II) affinity chromatog-
raphy. These conditions, coupled with maintaining the protein 
in an oxidised environment throughout, yielded 22 mg of 
monomeric His-PrP per liter of bacterial broth. The construct 
was designed to code for the mature part of the bovine prion 
protein (Fig. 1), i.e. lacking the N-terminal first 24 amino 
acids and the C-terminal last 16 amino acids [31,32]. Cross-
reactivity with antibodies against bovine PrP peptides, (parti-
al) Edman sequencing and mass of endoproteinase LysC 
products, electrophoretic behaviour and molecular mass of 
the recombinant protein, all indicate that His-PrP is correctly 
expressed. Moreover, susceptibility of the protein to protein-
ase K, from within the inclusion bodies to the final stage of 
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kl)a 
(l-265His-PrP) 
(134-265 His-PrP) 
(l38-265His-PrP) 
(42-l33Ilis-PrP) 
Fig. 3. Digestion of His-PrP by endoproteinase LysC. 15% SDS-PAGE of His-PrP treated with endo LysC (His-PrP: endo LysC, 100:1) for 
15 min (lane 2), 60 min (lane 3), or 120 min (lane 4). Lane 1: Untreated His-PrP. Peptides (shown at right) were identified on the basis of the 
determined average mass (Table 1) and of N-terminal sequencing for peptides 138-265 and 42-133 (see text). 
purification (not shown), strongly argues in favour of the 
identity of His-PrP with the PrPc isoform. 
Near- and far-UV CD analysis of His-PrP showed the pres-
ence, under the acidic conditions employed, of a tertiary struc-
ture with substantial oc-helical content. A comparison with 
CD data for other oxidised prion proteins is intrinsically dif-
ficult for several reasons. Unlike native hamster PrPc, His-
PrP contains an additional octapeptide repeat and an ex-
tended N-terminal tail, either of which may contribute to, 
or diminish, overall secondary structure content. Secondary 
structure determinations of full-length hamster PrPc were car-
ried out in the presence of the detergent Zwittergent 3-12 [3] 
which may increase ellipticity [33]. Lastly, literature reports 
until now have dealt with shorter PrP sequences (hamster 
90-231 sequence [16] and mouse 121-231 sequence [18]). 
The experiments with endoproteinase LysC may shed addi-
tional light on the structure of PrP. Of the 11 LysC peptide 
bonds in His-PrP, some are clearly more enzyme-accessible 
than others. Since digestion was carried out under non-de-
naturating, oxidised conditions, the sensitivity to cleavage of 
Lys41, Lys133 and Lys137 may indicate these amino acids to 
occur in regions lacking defined secondary structure [34]. In 
particular, the lysine in other PrP sequences corresponding to 
Lys137 of His-PrP was predicted to belong to an oc-helix do-
main [35], a model questioned by Hornemann and Glocks-
huber [18] based on the extensive proteolysis that takes place 
in this region of mouse PrP when periplasmically expressed. 
Attempts to express bovine PrP as a secretory protein were 
likewise unsuccesful (our unpublished observations). Togeth-
er, these data support the hypothesis that this region lacks a 
definite secondary structure in either mouse or ox PrP. Con-
versely, the higher resistance to proteolysis of His-PrP Lys231 
could reflect its belonging to an oc-helix, as predicted by 
Huang et al. [35] and confirmed by NMR structure determi-
nations [17]. 
In conclusion, we have developed a protocol whereby the 
mature part of bovine PrP (25-249), linked to a polyhistidine 
tag, is expressed intracellularly in bacteria and can be recov-
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ered intact. The intrinsic stability to proteolysis of the fused 
protein is most probably a consequence of the storage envi-
ronment (inclusion bodies) and/or of the extremely rapid syn-
thesis of large protein amounts induced by the T7 expression 
system. In spite of the extended N-terminus, His-PrP retained 
several characteristics expected for the non-infectious PrP iso-
form. The ideal recombinant protein, in which the N-terminal 
tag is removed, was not obtained although the plasmid was 
constructed for this purpose. The present expression system 
should, in every case, spur efforts at producing large amounts 
of intact PrP, thus overcoming difficulties in obtaining suffi-
cient quantities of PrP c for structural determinations. 
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